Murray Stahl's DGX Position Overview
Murray Stahl (via Horizon Kinetics Asset Management LLC) currently holds 2,900 shares of Quest Diagnostics Incorporated (DGX) worth $568,342, representing 0.01% of the portfolio. First purchased in 2013-Q2, this long-term strategic position has been held for 52 quarters.
Based on 13F filings since 2013, Murray Stahl has maintained a long-term strategic position in DGX, representing a significant commitment to this investment thesis. Largest addition occurred in Q3 2024, adding 1,050 shares. Largest reduction occurred in Q3 2025, reducing 2,100 shares.
Analysis based on 13F filings available since 2013 Q2
Murray Stahl's Quest Diagnostics Incorporated (DGX) Holding Value Over Time
Track share changes against reported price movement
Quarterly Quest Diagnostics Incorporated (DGX) Trades by Murray Stahl
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q1 2026 | -100 | Reduce 3.33% | 2,900 | $195.98 |
| Q3 2025 | -2,100 | Reduce 41.18% | 3,000 | $190.58 |
| Q2 2025 | -450 | Reduce 8.11% | 5,100 | $179.63 |
| Q1 2025 | -50 | Reduce 0.89% | 5,550 | $169.20 |
| Q3 2024 | +1,050 | Add 23.08% | 5,600 | $155.25 |
| Q1 2024 | -100 | Reduce 2.15% | 4,550 | $133.11 |
| Q3 2023 | -8 | Reduce 0.17% | 4,650 | $121.86 |
| Q2 2023 | +8 | Add 0.17% | 4,658 | $140.56 |
| Q1 2023 | -150 | Reduce 3.12% | 4,650 | $141.48 |
| Q1 2022 | -12 | Reduce 0.25% | 4,800 | $136.88 |
| Q4 2021 | -50 | Reduce 1.03% | 4,812 | $173.11 |
| Q2 2021 | +50 | Add 1.04% | 4,862 | $132.04 |
| Q1 2021 | -100 | Reduce 2.04% | 4,812 | $128.43 |
| Q3 2020 | -100 | Reduce 2.00% | 4,912 | $114.41 |
| Q2 2020 | +12 | Add 0.24% | 5,012 | $113.93 |
| Q1 2020 | -300 | Reduce 5.66% | 5,000 | $80.40 |
| Q1 2019 | +50 | Add 0.95% | 5,300 | $90.00 |
| Q4 2018 | -50 | Reduce 0.94% | 5,250 | $83.24 |
| Q3 2018 | -50 | Reduce 0.93% | 5,300 | $107.92 |
| Q2 2018 | -150 | Reduce 2.73% | 5,350 | $109.91 |
| Q1 2018 | -700 | Reduce 11.29% | 5,500 | $100.36 |
| Q4 2017 | -100 | Reduce 1.59% | 6,200 | $98.55 |
| Q3 2017 | -308 | Reduce 4.66% | 6,300 | $93.65 |
| Q2 2017 | -192 | Reduce 2.82% | 6,608 | $111.08 |
| Q1 2017 | -100 | Reduce 1.45% | 6,800 | $98.24 |
| Q4 2016 | -350 | Reduce 4.83% | 6,900 | $91.88 |
| Q3 2016 | -50 | Reduce 0.68% | 7,250 | $84.69 |
| Q2 2016 | -50 | Reduce 0.68% | 7,300 | $81.37 |
| Q4 2015 | -200 | Reduce 2.65% | 7,350 | $71.16 |
| Q2 2015 | +50 | Add 0.67% | 7,550 | $72.58 |
| Q1 2015 | -150 | Reduce 1.96% | 7,500 | $76.80 |
| Q4 2014 | -100 | Reduce 1.29% | 7,650 | $67.06 |
| Q3 2014 | +700 | Add 9.93% | 7,750 | $60.65 |
| Q2 2014 | -800 | Reduce 10.19% | 7,050 | $58.72 |
| Q1 2014 | +450 | Add 6.08% | 7,850 | $57.96 |
| Q4 2013 | +750 | Add 11.28% | 7,400 | $53.51 |
| Q3 2013 | +50 | Add 0.76% | 6,650 | $61.80 |
| Q2 2013 | +6,601 | Add 0.00% | 6,600 | $60.61 |
Murray Stahl's Quest Diagnostics Incorporated Investment FAQs
Murray Stahl first purchased Quest Diagnostics Incorporated (DGX) in Q2 2013, acquiring 6,600 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Murray Stahl has held Quest Diagnostics Incorporated (DGX) for 52 quarters since Q2 2013.
Murray Stahl's largest addition to Quest Diagnostics Incorporated (DGX) was in Q2 2013, adding 6,600 shares worth $400,000.
According to the latest 13F filing for Q1 2026, Murray Stahl's firm, Horizon Kinetics Asset Management LLC, owns 2,900 shares of Quest Diagnostics Incorporated (DGX), valued at approximately $568,342.
As of the Q1 2026 filing, Quest Diagnostics Incorporated (DGX) represents approximately 0.01% of Murray Stahl's publicly disclosed stock portfolio, making it one of their key holdings.
Murray Stahl's peak holding in Quest Diagnostics Incorporated (DGX) was 7,850 shares, as reported at the end of Q1 2014.